Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis

This study has been completed.

Sponsor:

Information provided by:

University of California, San Diego

ClinicalTrials.gov Identifier:

NCT00746889

First received: September 3, 2008

Last updated: July 29, 2010

Last verified: September 2008

History of Changes

Results First Received: April 5, 2010

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double-Blind; Primary Purpose: Treatment
Condition:	Osteoarthritis
Interventions:	Drug: triamcinolone acetonide Drug: saline

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients were recruited in rheumatology clinics at UCSD and the VA musculoskeletal clinic.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Patients taking oral corticosteroids, who had a primary inflammatory connective tissue disease, or who received IA corticosteroids in the affected knee within three months of study entry were excluded from the study.

Reporting Groups

	Description
Corticosteroid Injection	40 mg of intraarticular triamcinolone acetonide
Placebo	Intraarticular injection of 0.9% saline

Participant Flow: Overall Study

	Corticosteroid Injection	Placebo
STARTED	40	39
COMPLETED	36	35
NOT COMPLETED	4	4

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Corticosteroid Injection	40 mg of intraarticular triamcinolone acetonide
Placebo	Intraarticular injection of 0.9% saline
Total	Total of all reporting groups

Baseline Measures

	Corticosteroid Injection	Placebo	Total
Number of Participants [units: participants]	40	39	79
Age [units: participants]
<=18 years	0	0	0
Between 18 and 65 years	24	23	47
>=65 years	16	16	32
Age [units: years] Mean ± Standard Deviation	64 ± 12	63 ± 12	63 ± 12
Gender [units: participants]
Female	1	2	3
Male	39	37	76
Region of Enrollment [units: participants]
United States	40	39	79

Outcome Measures

Show All Outcome Measures

1. Primary:

Change in Western Ontario and McMasters Universities Arthritis Index (WOMAC) Pain Subscale [ Time Frame: baseline to 4 weeks ]

Show Outcome Measure 1

2. Other Pre-specified:

Change in WOMAC Pain Subscale [ Time Frame: baseline to 12 weeks ]

Show Outcome Measure 2

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Title: Jeannie Chao
Organization: UCSD
phone: 858-657-7040
e-mail: j5chao@ucsd.edu

No publications provided

Responsible Party:	Kenneth Kalunian, University of California San Diego
ClinicalTrials.gov Identifier:	NCT00746889 History of Changes
Other Study ID Numbers:	IRB 051420
Study First Received:	September 3, 2008
Results First Received:	April 5, 2010
Last Updated:	July 29, 2010
Health Authority:	United States: Institutional Review Board

To Top